Incidence and management of cutaneous toxicities associated with cetuximab

Expert Opinion on Drug Safety

Volumn 6, Issue 2, 2007, Pages 175-182

  Saif, M Wasif ^a   Kim, Richard ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Cetuximab; Colorectal cancer; Erbitux; Paronychia; Rash

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BACTROBAN NASAL; BENZOYL PEROXIDE; CETIRIZINE; CETUXIMAB; CLINDAMYCIN; CLOBETASOL PROPIONATE; DOXYCYCLINE; EMOLLIENT AGENT; ERLOTINIB; ERYTHROMYCIN; FUSIDIC ACID; HEXAMIDINE; HYDROCORTISONE VALERATE; HYDROXYZINE; IMMUNOMODULATING AGENT; IRINOTECAN; LORATADINE; METRONIDAZOLE; MINOCYCLINE; PANITUMUMAB; PIMECROLIMUS; PLATINUM COMPLEX; POVIDONE IODINE; PSEUDOMONIC ACID; RETINOID; STEROID; TETRACYCLINE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ACNE; AIRWAY OBSTRUCTION; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOPULMONARY ARREST; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DIMERIZATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; ERYTHEMA; FATIGUE; HEAD AND NECK CANCER; HUMAN; HYDROTHERAPY; HYPOMAGNESEMIA; HYPOTENSION; INCIDENCE; INTERSTITIAL LUNG DISEASE; LOADING DRUG DOSE; LUNG CANCER; LYMPHOMA; MACULOPAPULAR RASH; MONOTHERAPY; NAIL DISEASE; NAIL PIGMENTATION; NAUSEA; NAUSEA AND VOMITING; PANCREAS CANCER; PATHOGENESIS; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PROTEIN EXPRESSION; PRURITUS; PUSTULE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN ABRASION; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN CARE; SKIN EXFOLIATION; SKIN MANIFESTATION; SKIN REDNESS; SKIN TOXICITY; SUDDEN DEATH; SYSTEMIC THERAPY; TREATMENT PLANNING; URTICARIA; WASTING SYNDROME; WEAKNESS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COLORECTAL NEOPLASMS; EXANTHEMA; HUMANS; INCIDENCE;

EID: 33847717475     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.2.175     Document Type: Review

References (32)

1. WONG SF: Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin. Ther. (2005) 27(6):684-694.
2. MENDELSOHN J: Blockade of receptors for growth factors: an anticancer therapy - the fourth annual Joseph H. Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin. Cancer Res. (2000) 6:747-753.
3. BASELGA J, NORTON L, MASUI H: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Nod. Cancer Inst. (1993) 85:1327-1333.
4. SALTZ LB, MEROPOL NJ, LOEHRER PJ Sr et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22:1201-1208.
5. CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351(4):337-345.
6. BONNER JA, HARARI PM, GIRALT J et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. (2006) 354(6):567-578.
7. TRIGO J, HITT R, KORALEWSKI P et al.: Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a Phase II study. Proc. Am. Soc. Clin. Oncol. (2004):A5502.
8. SCHRAG D, CHUNG KY, FLOMBAUM C, SALTZ L: Cetuximab therapy and symptomatic hypomagnesemia. J. Natl. Cancer Inst. (2005) 97:1221-1224.
9. BASELGA J, PFISTER D, COOPER MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. (2000) 18:904-914.
10. ROBERT F, EZEKIEL M, SPENCER SA et al.: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. (2001) 19:3234-3243.
11. BASELGA J, RISCHIN D, RANSON M et al.: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD-1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. (2002) 20:4292-4302.
12. VAN DOORN R, KIRTSCHIG G, SCHEFFER E, STOOF TJ, GIACCONE G: Follicular and epidermal alterations in patients treated with ZD-1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br. J. Dermatol. (2002) 147:598-601.
13. HIDALGO M, SIU LL, NEMUNAITIS J et al.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. (2001) 19:3267-3279.
14. HERBST RS, LORUSSO PM, PURDOM M, WARD D: Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin. Lung Cancer (2003) 4:366-369.
15. PURDOM M: Management of acneiform rashes related to gefitinib therapy. Clin. J. Oncol. Nurs. (2004) 8:316-317.
16. LAUX I, JAIN A, SINGH S, AGUS DB: Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br. J. Cancer (2006) 94(1):85-92.
17. ALBANELL J, ROJO F, AVERBUCH S et al.: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD-1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. (2002) 20:110-124.
18. SALTZ L, KIES M, ABBRUZZESE JL et al.: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol. (2003):A204.
19. TEJPAR S, PEETERS M, HUMBLET Y et al.: Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data. Proc. Am. Soc. Clin. Oncol. (2006):A3554.
20. VAN CUTSEM E, MAYER RJ, GOLD P et al.: Correlation of acne rash and tumour response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Eur. J. Cancer (2004) 85(Suppl. 2):Abstract 279.
21. SIPPLES R: Common side effects of anti-EGFR therapy: acneform rash. Semin. Oncol. Nurs. (2006) 22(1 Suppl. 1):28-34.
22. PÉREZ-SOLER R, DELORD JP, HALPERN A et al.: HER1/EGFR inhibitor-associated rash future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist (2005) 10:345-356.
23. JACOT W, BESSIS D, JORDA E et al.: Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br. J. Dermatol. (2004) 151:238-241.
24. SHAH NT, KRIS MG, PAO W et al.: Practical management of patients with non-small-cell lung cancer treated with gefitinib. J. Clin. Oncol. (2005) 23:165-174.
25. Erbitux (cetuximab) [package insert]. ImClone Systems Incorporated, New York, NY, and Bristol-Myers Squibb Company, Princeton, NJ, USA (2005).
26. MOSS JE, BURTNESS B: Cetuximab-associated acneiform eruption. N. Engl. J. Med. (2005) 19(e17):353.
27. RHEE J, OISHI K, GAREY J, KIM E: Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. Clin. Colorectal Cancer (2005) 5(Suppl. 2):S101-S106.
28. SAPADIN AN, FLEISCHMAJER R: Tetracyclines: nonantibiotic properties and their clinical implications. J. Am. Acad. Dermatol. (2006) 54(2):258-265.
29. SHAPIRO LE, KNOWLES SR, SHEAR NH: Comparative safety of tetracycline, minocycline, and doxycycline. Arch. Dermatol. (1997) 133:12240-12230.
30. BUSAM KJ, CAPODIECI P, MOTZER R et al.: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br. J. Dermatol. (2001) 144:1169-1176.
31. SEGAERT S, TABERNERO J, CHOSIDOW O et al.: The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J. Dtsch Dermatol. Ges. (2005) 3(8):599-606.
32. PEREZ-SOLER R, SALTZ L: Cutaneous adverse effects with HER1/ EGFR-targeted agents:is there a silver lining? J. Clin. Oncol. (2005) 23(22):5235-5246.